{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:23:34Z","timestamp":1772648614391,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00277-023-05432-x","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:01:47Z","timestamp":1693897307000},"page":"3489-3497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3210-7756","authenticated-orcid":false,"given":"Taku","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Kunisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Nomura-Yogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"2","key":"5432_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132\u2013147. https:\/\/doi.org\/10.1056\/NEJMoa2204925","journal-title":"N Engl J Med"},{"issue":"25","key":"5432_CR2","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/jco.21.01935","volume":"40","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D\u2019Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS (2021) Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 40(25):2901\u20132912. https:\/\/doi.org\/10.1200\/jco.21.01935","journal-title":"J Clin Oncol"},{"issue":"6","key":"5432_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.18654","volume":"200","author":"D Minakata","year":"2023","unstructured":"Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y (2023) Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol 200(6):694\u2013703. https:\/\/doi.org\/10.1111\/bjh.18654","journal-title":"Br J Haematol"},{"issue":"2","key":"5432_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.24954","volume":"93","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK (2018) Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma. Am J Hematol 93(2):179\u2013186. https:\/\/doi.org\/10.1002\/ajh.24954","journal-title":"Am J Hematol"},{"issue":"22","key":"5432_CR5","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.2169\/internalmedicine.9097-21","volume":"61","author":"T Togano","year":"2022","unstructured":"Togano T, Andoh S, Komuro M, Mitsui Y, Itoi S, Hirai R, Nakamura M, Tanimura A, Sekine R, Takeshita M, Miwa A, Hagiwara S (2022) Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a salvage and bridging regimen before hematopoietic stem cell transplantation for relapsed or refractory multiple myeloma. Intern Med 61(22):3329\u20133334. https:\/\/doi.org\/10.2169\/internalmedicine.9097-21","journal-title":"Intern Med"},{"issue":"20","key":"5432_CR6","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1002\/cncr.29533","volume":"121","author":"PT Griffin","year":"2015","unstructured":"Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC (2015) A comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma. Cancer 121(20):3622\u20133630. https:\/\/doi.org\/10.1002\/cncr.29533","journal-title":"Cancer"},{"issue":"1","key":"5432_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00277-022-05027-y","volume":"102","author":"S Ghandili","year":"2023","unstructured":"Ghandili S, Alihodzic D, Wiessner C, Bokemeyer C, Weisel K, Leypoldt LB (2023) VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed\/refractory multiple myeloma: a single-center experience. Ann Hematol 102(1):117\u2013124. https:\/\/doi.org\/10.1007\/s00277-022-05027-y","journal-title":"Ann Hematol"},{"issue":"8","key":"5432_CR8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos M-V, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau J-L, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"3","key":"5432_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5432_CR10","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/bjh.17248","volume":"192","author":"L Ainley","year":"2021","unstructured":"Ainley L, Chavda SJ, Counsell N, Cheesman S, Newrick F, Horder J, Kyriakou C, Papanikolaou X, Sive J, Lee L, Wechalekar A, Mehta A, Popat R, Rabin N, Yong K (2021) DT-PACE\/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. Br J Haematol 192(3):e73\u2013e77. https:\/\/doi.org\/10.1111\/bjh.17248","journal-title":"Br J Haematol"},{"issue":"6","key":"5432_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjh.12325","volume":"161","author":"AS Gerrie","year":"2013","unstructured":"Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, Reece D, Stewart KA, Trieu Y, Trudel S, Chen CI (2013) D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol 161(6):802\u2013810. https:\/\/doi.org\/10.1111\/bjh.12325","journal-title":"Br J Haematol"},{"issue":"2","key":"5432_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ejh.13422","volume":"105","author":"F Djebbari","year":"2020","unstructured":"Djebbari F, De Abrew K, Salhan B, Panitsas F, Hossain MI, Eyre TA, Willan J, Ramasamy K, Basu S, Jenner M, Kothari J (2020) DPACE-based chemotherapy in the era of myeloma novel agents: a UK multicentre study. Eur J Haematol 105(2):231\u2013233. https:\/\/doi.org\/10.1111\/ejh.13422","journal-title":"Eur J Haematol"},{"issue":"9","key":"5432_CR13","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1080\/10428194.2021.1907373","volume":"62","author":"T Huynh","year":"2021","unstructured":"Huynh T, Corre E, Lemonnier MP, Dul\u00e9ry R, Marjanovic Z, Jaff N, Lapusan S, Mohty M, Garderet L, Coppo P (2021) Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leuk Lymphoma 62(9):2235\u20132241. https:\/\/doi.org\/10.1080\/10428194.2021.1907373","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"5432_CR14","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/j.clml.2020.09.002","volume":"21","author":"AO Abdallah","year":"2021","unstructured":"Abdallah AO, Sigle M, Mohyuddin GR, Coggins E, Remker C, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S (2021) Outcomes of VD-PACE with immunomodulatory agent as a salvage therapy for relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 21(2):e220\u2013e226. https:\/\/doi.org\/10.1016\/j.clml.2020.09.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"5432_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.clml.2021.03.013","volume":"21","author":"A Alsouqi","year":"2021","unstructured":"Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF (2021) KD-PACE salvage therapy for aggressive relapsed refractory multiple myeloma, plasma cell leukemia and extramedullary myeloma. Clin Lymphoma Myeloma Leuk 21(8):526\u2013535. https:\/\/doi.org\/10.1016\/j.clml.2021.03.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"5432_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.clml.2020.04.002","volume":"20","author":"AJ Cowan","year":"2020","unstructured":"Cowan AJ, Green DJ, Karami M, Becker PS, Tuazon S, Coffey DG, Hyun TS, Libby EN, Gopal AK, Holmberg LA (2020) KRD-PACE mobilization for multiple myeloma patients with significant residual disease before autologous stem-cell transplantation. Clin Lymphoma Myeloma Leuk 20(9):602\u2013609. https:\/\/doi.org\/10.1016\/j.clml.2020.04.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"29","key":"5432_CR17","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall\u2019Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Blad\u00e9Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, D\u00fcrig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hern\u00e1ndez Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: a European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol 40(29):3406\u20133418. https:\/\/doi.org\/10.1200\/JCO.21.02614","journal-title":"J Clin Oncol"},{"issue":"5","key":"5432_CR18","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"M-V Mateos","year":"2022","unstructured":"Mateos M-V, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, Van De Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36(5):1371\u20131376. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"issue":"3","key":"5432_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosi\u00f1ol L, Usmani SZ, Zamagni E, Richardson P (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12(3):45. https:\/\/doi.org\/10.1038\/s41408-022-00643-3","journal-title":"Blood Cancer J"},{"issue":"9","key":"5432_CR20","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ (2019) Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33(9):2266\u20132275. https:\/\/doi.org\/10.1038\/s41375-019-0435-7","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05432-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:04:04Z","timestamp":1699679044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05432-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5432"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05432-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the JRCMC Institutional Review Board and was conducted under an abbreviated informed consent procedure and an opt-out consent principle. None of the included participants requested to be removed from the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"TK received personal fees from Janssen, Takeda, and Sanofi. NT received personal fees from Janssen and Sanofi. TI received honoraria from Ono, Takeda, Celgene\/Bristol-Myers Squibb, and Janssen. KS received honoraria from Takeda, Celgene, Ono, Amgen, Novartis, Sanofi, BMS, AbbVie, and Janssen; consultancy fees from Takeda, Amgen, Janssen, and Celgene; and research funding from BMS, Celgene, and Amgen. The authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}